No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma

J Immunother. 2009 Oct;32(8):884-5. doi: 10.1097/CJI.0b013e3181affbf0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Blocking / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibody Formation*
  • Antigens, CD / immunology*
  • Antigens, Neoplasm / immunology*
  • CTLA-4 Antigen
  • Clinical Trials as Topic
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunoglobulins / blood
  • Ipilimumab
  • Melanoma / blood
  • Melanoma / drug therapy*
  • Melanoma / immunology*
  • Melanoma / pathology
  • Membrane Glycoproteins / administration & dosage
  • Membrane Proteins / immunology*
  • Neoplasm Metastasis
  • Peptide Fragments / administration & dosage
  • gp100 Melanoma Antigen

Substances

  • Antibodies, Blocking
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Neoplasm
  • CTAG1B protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immunoglobulins
  • Ipilimumab
  • Membrane Glycoproteins
  • Membrane Proteins
  • PMEL protein, human
  • Peptide Fragments
  • gp100 Melanoma Antigen